Fielder Capital Group LLC Makes New Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

Fielder Capital Group LLC bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 481 shares of the medical research company’s stock, valued at approximately $255,000.

Several other large investors also recently added to or reduced their stakes in TMO. Machina Capital S.A.S. boosted its holdings in shares of Thermo Fisher Scientific by 96.2% during the 4th quarter. Machina Capital S.A.S. now owns 3,924 shares of the medical research company’s stock worth $2,083,000 after buying an additional 1,924 shares during the period. Maryland State Retirement & Pension System boosted its holdings in shares of Thermo Fisher Scientific by 1.1% during the 4th quarter. Maryland State Retirement & Pension System now owns 30,036 shares of the medical research company’s stock worth $15,943,000 after buying an additional 320 shares during the period. Private Advisor Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 88.0% during the 4th quarter. Private Advisor Group LLC now owns 21,996 shares of the medical research company’s stock worth $11,676,000 after buying an additional 10,295 shares during the period. MeadowBrook Investment Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $1,824,000. Finally, Clifford Swan Investment Counsel LLC boosted its holdings in shares of Thermo Fisher Scientific by 2.9% during the 4th quarter. Clifford Swan Investment Counsel LLC now owns 755 shares of the medical research company’s stock worth $401,000 after buying an additional 21 shares during the period. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded up $1.16 during mid-day trading on Monday, reaching $573.54. 1,140,681 shares of the stock were exchanged, compared to its average volume of 1,544,948. The company has a market cap of $218.93 billion, a price-to-earnings ratio of 36.79, a price-to-earnings-growth ratio of 2.37 and a beta of 0.80. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The firm has a 50-day simple moving average of $575.59 and a 200 day simple moving average of $534.36. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a $0.39 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Analysts Set New Price Targets

A number of analysts have weighed in on TMO shares. JPMorgan Chase & Co. increased their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Raymond James increased their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Deutsche Bank Aktiengesellschaft increased their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Finally, Evercore ISI increased their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $607.35.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,873,516.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The disclosure for this sale can be found here. Insiders have sold 62,277 shares of company stock worth $35,373,364 in the last three months. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.